Aptevo Offloads Ruxience Biosimilar Rights In $67.5m Deal
Aptevo currently receives a 2.5% royalty from Pfizer
Executive Summary
The royalties for Pfizer’s Ruxience biosimilar, which has achieved a near 25% penetration rate in the US market, are to fall into the hands of another party following an agreement by original holder Aptevo Therapeutics. Teva’s Truxima is reported to be market leader in the US.
You may also be interested in...
Deal Watch: Roche Links With SemaThera, Acquires GenMark Diagnostics
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
Amgen’s Mvasi Biosimilar Overtakes Avastin In The US
Amgen enters 2021 with a five-strong global biosimilars portfolio, spearheaded by its market-leading bevacizumab and trastuzumab products in the US. Management explained the contrasting fates of the two oncology biosimilars as it published full-year financial results.
Teva CEO Schultz: ‘Proof Is In The Pudding’ For US Biosimilars
Teva CEO Kåre Schultz believes his prediction is coming true for the Truxima biosimilar in-licensed from Celltrion, as he gave the latest update on Teva’s efforts to settle significant legal issues around the US opioid crisis.